Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | MAPK14 | Q16539 | 9/20 | 0.33 |
| ▸ | KCNJ5 | P48544 | 1/20 | 0.32 |
| ▸ | KCNJ3 | P48549 | 1/20 | 0.32 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.31 |
| ▸ | TRPV6 | Q9H1D0 | 1/20 | 0.31 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.30 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.30 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30034762 | 0.91 | NR1H4 (0.36) | NR1H4NPC1ALDH1A1RAB9ASMN1; SMN2 | |
| SCHEMBL30807043 | 0.91 | NR1H4 (0.41) | NR1H4MAPK14 | |
| SCHEMBL20833800 | 0.91 | NR1H4 (0.36) | NR1H4NPC1ALDH1A1RAB9ASMN1; SMN2 | |
| SCHEMBL20833879 | 0.91 | NR1H4 (0.41) | NR1H4MAPK14 | |
| SCHEMBL17839932 | 0.87 | NR1H4 (0.41) | NR1H4NPC1ALDH1A1RAB9ASMN1; SMN2 | |
| SCHEMBL1097296 | 0.86 | NR1H4 (0.40) | NR1H4NPC1ALDH1A1RAB9ASMN1; SMN2 | |
| SCHEMBL1095874 | 0.86 | NR1H4 (0.42) | NR1H4NPC1ALDH1A1RAB9ASMN1; SMN2 | |
| SCHEMBL2772447 | 0.81 | NR1H4 (0.39) | NR1H4NPC1ALDH1A1RAB9ASMN1; SMN2 | |
| SCHEMBL22392553 | 0.80 | NR1H4 (0.41) | NR1H4NPC1ALDH1A1RAB9ASMN1; SMN2 | |
| SCHEMBL28410381 | 0.79 | NR1H4 (0.44) | NR1H4NPC1ALDH1A1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111655680-B | Hormone receptor modulators for the treatment of metabolic mutations and fibrotic conditions and disorders | 阿德利克斯股份有限公司 | 2024-03-05 | — | — | CN | disclosed |
| US-11753410-B2 | Hormone receptor modulators for treating metabolic mutagenic and fibrotic conditions and disorders | ARDELYX, INC. (US) | 2023-09-12 | — | — | US | disclosed |
| US-11753410-B2 | Hormone receptor modulators for treating metabolic mutagenic and fibrotic conditions and disorders | ARDELYX, INC. (US) | 2023-09-12 | — | — | US | disclosed |
| US-11753410-B2 | Hormone receptor modulators for treating metabolic mutagenic and fibrotic conditions and disorders | ARDELYX, INC. (US) | 2023-09-12 | — | — | US | disclosed |
| EP-3681881-B1 | HORMONE RECEPTOR MODULATORS FOR TREATING METABOLIC MUTAGENIC AND FIBROTIC CONDITIONS AND DISORDERS | ARDELYX INC (US) | 2022-11-02 | — | — | EP | disclosed |
| US-20210380585-A1 | HORMONE RECEPTOR MODULATORS FOR TREATING METABOLIC MUTAGENIC AND FIBROTIC CONDITIONS AND DISORDERS | ARDELYX, INC. (US) | 2021-12-09 | — | — | US | disclosed |
| WO-2019055808-A1 | HORMONE RECEPTOR MODULATORS FOR TREATING METABOLIC MUTAGENIC AND FIBROTIC CONDITIONS AND DISORDERS | ARDELYX, INC. (US) | 2019-03-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210380585-A1 | HORMONE RECEPTOR MODULATORS FOR TREATING METABOLIC MUTAGENIC AND FIBROTIC CONDITIONS AND DISORDERS | NR1H4, FXR1, FXR2 | NR1H4 1/4885NPC1 2959/4885ALDH1A1 1318/4885 |
| US-11753410-B2 | Hormone receptor modulators for treating metabolic mutagenic and fibrotic conditions and disorders | NR1H4, FXR1, FXR2 | NR1H4 1/4885NPC1 2959/4885ALDH1A1 1318/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.